Simulations PlusNASDAQ: SLP

Simulations Plus NASDAQ: SLP is a small-cap healthcare technology company with a value of about $800 million. The firm has vastly underperformed the market and its sector over the last 12 months, with a total return of -7%.

Simulations Plus' (SLP) fiscal third-quarter revenues are driven by strength in Software and Services units.

Simulations Plus, Inc. (NASDAQ:SLP ) Q3 2024 Earnings Conference Call July 2, 2024 5:00 PM ET Company Participants Lisa Fortuna - Investor Relations, Financial Profiles Shawn O'Connor - Chief Executive Officer Will Frederick - Chief Financial Officer & Chief Operating Officer Conference Call Participants Christine Rains - William Blair François Brisebois - Oppenheimer & Company Matt Hewitt - Craig-Hallum David Larsen - BTIG Operator Greetings, and welcome to the Simulations Plus Third Quarter Fiscal 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Simulations Plus (SLP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Simulations Plus (SLP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Simulation Plus (SLP) acquires Pro-ficiency from QHP Capital for $100 million in an all-cash transaction.

Simulations Plus (SLP) introduces GastroPlus X, which greatly decreases the time needed for model setup, data organization, and result formatting.

For the seventh consecutive year, the FDA has renewed Simulations Plus' (SLP) license to the DILIsym software system for facilitating drug safety evaluations.

Simulations Plus' (SLP) second-quarter fiscal 2024 top line is driven by higher revenues in the Software and Services business segments.